New CDK Inhibitors

Catalog No. Product Name Information
E8310 Ribociclib succinate hydrate Ribociclib succinate hydrate is an orally bioavailable and selective, inhibitor of both CDK4 and CDK6 with IC50 values of 10 nM and 39 nM, respectively. It exhibits anticancer activitiy and can be used in breast cancer, melanoma, liposarcoma, non–small cell lung cancer, and neuroblastoma therapy research.
E8287 YX0597 YX0597 is a potent and selective CDK9 PROTAC degrader that reduces RNA polymerase II S2 phosphorylation and MCL1 expression in GA0518 and AGS cells. It effectively inhibits GEAC cell growth, including radiation-resistant tumors, and suppresses tumor proliferation, metastasis, and cancer stem cells.
E8303 YJ9069 YJ9069 is a potent, selective and orally bioavailable PROTAC degrader of CDK12/CDK13. It inhibits proliferation in prostate cancer cells by inducing gene-length-dependent transcriptional elongation defects, leading to DNA damage, cell-cycle arrest, and significant tumor growth suppression in vivo.
E1725 T025 T025 is as an orally available and potent inhibitor of Cdc2‐like kinases (CLKs) with an IC50s of 0.93 nM, 1 nM, 14 nM, 1.5 nM for CLK1, CLK2, CLK3, DYRK1B respectively. It exhibits anti‐tumor efficacy and can be used in MYC‐driven cancer research.
E1455 BTX-A51 BTX-A51 (Casein Kinase inhibitor A51) is a first-in-class oral and potent inhibitor of casein kinase 1α (CK1α) and cyclin dependent kinase (CDK7/9) with an IC50 of 17 nM for CK1α and Kd of 1.3 nM and 4 nM for CDK7 and CDK9, respectively. It induces apoptosis of leukemic cells by activating p53 and inhibiting expression of Mcl1 and can be used in Acute myeloid leukemia (AML) cancer research.
All CDK Inhibitors